RCM
ABBV icon

Ravenstone Capital Management’s AbbVie ABBV Stock Holding History

Ravenstone Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21
Closed -$4.57K – 54
2026
Q1 		$4.57K Buy
+21
New +$4.66K ﹤0.01% 46
2025
Q1 		– Sell
-200
Closed -$35.5K – 91
2024
Q4 		$35.5K Buy
+200
New +$36.8K 0.02% 71

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ravenstone Capital Management's ABBV Position: Q2 2026 in Review

Ravenstone Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 21 shares — an estimated $4.57K sold.

Ravenstone Capital Management first reported a position in ABBV in Q4 2024 and held it in 2 quarters. The position peaked at $35.5K in Q4 2024. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Ravenstone Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
  • Ravenstone Capital Management sold 21 AbbVie shares in Q2 2026, an estimated $4.57K.
  • Ravenstone Capital Management first reported a position in AbbVie in Q4 2024 and held it in 2 quarters.
  • Ravenstone Capital Management's AbbVie position peaked at $35.5K in Q4 2024.
  • 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ravenstone Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.